Future Directions in the Treatment of Mantle Cell Lymphoma
Kami Maddocks, MD, and Alexey Danilov, MD, PhD, close their discussion with a look at the future treatment landscape of mantle cell lymphoma.
Evaluating Pirtobrutinib in Patients with R/R Mantle Cell Lymphoma
Experts discuss data on pirtobrutinib, a non-covalent BTK inhibitor, in the treatment of patients with relapsed/refractory mantle cell lymphoma.
Data on Covalent BTK Inhibitors for the Treatment of R/R Mantle Cell Lymphoma
Drs Kami Maddocks and Alexey Danilov review data from ongoing studies evaluating covalent BTK inhibitors in relapsed/refractory mantle cell lymphoma.
Bruton Kinase Inhibitors for Relapsed/Refractory Mantle Cell Lymphoma
Kami Maddocks, MD, and Alexey Danilov, MD, PhD, discuss the evolution of BTK inhibitors and how they have changed treatment approaches in clinical practice.
Role of Maintenance Therapy in Newly Diagnosed Mantle Cell Lymphoma
Experts explain the role of maintenance therapy in mantle cell lymphoma and how it impacts the risk of disease progression.
Common Frontline Therapy Approaches for Patients With Mantle Cell Lymphoma
Drs Kami Maddocks and Alexey Danilov review the frontline therapy options for patients with mantle cell lymphoma based on risk status.
Overview of Mantle Cell Lymphoma
Kami Maddocks, MD, and Alexey Danilov, MD, PhD, provide an overview of mantle cell lymphoma, including prevalence and common risk factors.
Dr. Maddocks on the Investigation of Noncovalent BTK Inhibitors in MCL
Kami J. Maddocks, MD, discusses the investigation of noncovalent BTK inhibitors in mantle cell lymphoma.
Concluding Thoughts on the DLBCL Treatment Landscape
DLBCL experts share their thoughts on the changing treatment landscape and emerging treatments in large B-cell lymphomas.
Use of CAR T-Cell Therapies in Earlier Lines of DLBCL
Panelists discuss data on the use of CAR T-cell therapies in earlier lines and implications of these data on the DLBCL treatment landscape going forward.
Monoclonal Antibodies for Treatment of R/R DLBCL
Dr Nowakowski shares data from CD19-targeting monoclonal antibodies in treatment of R/R DLBCL.
Real-World Data With CAR-T Therapies in R/R DLBCL
Dr Westin discusses real-world data with CAR T-cell therapies in R/R DLBCL that were presented at ASH 2021.
Safety With CAR-T Therapies in R/R DLBCL
Dr Maziarz provides an overview of adverse events with CAR T-cell therapies and approaches to managing toxicities.
CAR-T Therapies in R/R DLBCL
Panelists discuss data with CAR T-cell therapies in treatment of relapsed and refractory DLBCL.
Dr Miklos provides an overview of chimeric antigen receptor T (CAR-T) cell therapy.
Refractory vs Relapsed Patients with Diffuse Large B-Cell Lymphoma
Dr Nowakowski discusses patient heterogeneity and treatment of relapsed vs refractory patients with DLBCL.
Relapsed and Refractory Diffuse Large B-Cell Lymphoma
A panel of diffuse large B-cell lymphoma experts discuss patient criteria and treatment selection in relapsed/refractory DLBCL.
Front-Line Treatment of DLBCL
Drs Westin, Miklos, and other panelists discuss the standard of care and emerging frontline treatments for diffuse large B-cell lymphoma.
Diffuse Large B-Cell Lymphoma Overview: An Aggressive Heterogenous Disease
A panel of oncologists talks about diffuse large B-cell lymphoma, what patient and disease factors one should take into account when thinking about DLBCL.
Dr. Maddocks on Ongoing Sequencing Challenges in DLBCL
Kami J. Maddocks, MD, discusses ongoing sequencing challenges in diffuse large B-cell lymphoma.
Dr. Maddocks on Remaining Challenges in Follicular Lymphoma
Kami J. Maddocks, MD, discusses remaining challenges in treating patients with follicular lymphoma.
Dr. Maddocks on Unanswered Questions With BTK Inhibitors in B-Cell Malignancies
Kami J. Maddocks, MD, discusses unanswered questions with BTK inhibitors in B-cell malignancies.
Dr. Maddocks on the Role of Tazemetostat in EZH2-Mutant Follicular Lymphoma
Kami J. Maddocks, MD, discusses the role of tazemetostat in patients with EZH2-mutant follicular lymphoma.
Dr. Maddocks on Emerging Therapies in Follicular Lymphoma
Kami J. Maddocks, MD, discusses emerging therapies in follicular lymphoma.
Dr. Maddocks on Treatment Considerations in Follicular Lymphoma
Kami J. Maddocks, MD, discusses treatment considerations for treatment selection in follicular lymphoma.
Dr. Maddocks on the Role of Zanubrutinib in B-Cell Malignancies
Kami J. Maddocks, MD, discusses the role of zanubrutinib in B-cell malignancies.
Lung Responses to Atezolizumab/Bevacizumab Linked With OS in HCC and Pulmonary Metastasis
Second-Line Regorafenib Demonstrates Safety in Advanced HCC, Irrespective of Prior Treatment
First-line Toripalimab Plus Sorafenib Elicits Responses in Unresectable Hepatocellular Carcinoma
Data for Luspatercept Highlight Evolving Treatment Landscape in Lower-Risk MDS
2 Clarke Drive Cranbury, NJ 08512